Druggability Technologies Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and New President of DRGT Research

BUDAPEST, Hungary, Oct. 21, 2019 (GLOBE NEWSWIRE) — Druggability Technologies Holdings, Ltd (DRGT), Ltd a clinical stage specialty pharmaceutical company, announced the appointment of Lynne Powell as Chief Executive Officer (CEO). Lynne will also be joining the company’s Board of Directors. Lynne will succeed Gabor Heltovics, who will continue to serve as President, DRGT Research and remain on the Board of Directors.

“I’m delighted to welcome Lynne to the company as we transition to Phase 3 clinical development. Lynne brings an impressive track record of operational and commercial leadership, including multiple successful product launches,” Andrew Midler, Chairperson of the Board noted.

Ms. Powell has more than 25 years’ experience in the biopharmaceutical/ biotechnology industry. Prior to DRGT she served as Chief Commercial Office at BioCryst, an emerging biotechnology company focused on commercializing innovative small molecules. Before this, she was Senior Vice President, North America, at CSL Behring. Throughout her 17-year career at CSL Behring, she assumed increasing responsibilities within the R&D and commercial functions of the organization. Lynne has significant global experience serving as Vice President, Global Commercial Development and Head of Business Development & European Marketing, Head of Project and Portfolio Management and Head of Clinical Research. Ms. Powell also held positions within Glaxo Wellcome’s commercial strategy and clinical research organizations.

Ms. Powell noted that “I am excited to be joining the DRGT team as we move forward 5 clinical stage compounds and are actively advancing our research pipeline in diseases with high unmet medical need.” Ms. Powell will be based in the United States in DRGT USA’s offices.

With the appointment of Ms. Powell, Mr. Midler also thanked Gabor Heltovics, the founding CEO of DRGT for his vision and leadership. “Under Mr Heltovics’ guidance, DRGT has grown from a 2-person company to an organization that is developing 5 clinical stage compounds for major indications as well as an innovative pre-clinical pipeline following closely in their footsteps. Mr. Heltovics will continue to have an important and leading role in the organization, serving as a member of the Board of Directors and as President of DRGT Research.” Mr. Heltovics observed, “We are ready to take the next step and develop into a fully integrated, commercial pharmaceutical company. I am thrilled that Lynne has come on board to lead the organization in this crucial next phase of our journey.”

About DRGT

DRGT is a specialty pharmaceutical company dedicated to the development and commercialization of high-value proprietary drugs that deliver measurable and meaningful improvements in clinical utility. The company was founded by Dr. Ferenc Darvas, who is also the Chairman of the oldest Hungarian upstream-technology network.

Lynne Powell, CEO
E-mail: [email protected]
Phone: +36-1-5779-300